Clinical Trials | January 15, 2026
Boehringer Ingelheim and Jazz Pharma team up on novel HER2-positive breast cancer therapy
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
Subscribe To Our Newsletter & Stay Updated
